"bms" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonChris Shibutani, MD - Bristol Myers Squibb (BMS)
Chris Shibutani, MD Bristol Myers Squibb (BMS)
Chutes & Ladders— BMS banks on Wall Street vet for long-term strategy guidance - Fierce Biotech
Chutes & Ladders— BMS banks on Wall Street vet for long-term strategy guidance Fierce Biotech
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer ...
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment geneonline.com
BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem - BioSpace
BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem BioSpace
ESPN SportsCenter Coming to BMS - Johnson City Press
ESPN SportsCenter Coming to BMS Johnson City Press
Biogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness categor...
Biogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness category Fierce Pharma
Capturing Kids’ Hearts - BMS Named A Rising Star School - TAPinto
Capturing Kids’ Hearts - BMS Named A Rising Star School TAPinto
BMS Announces $11.1 Billion Deal to Work with BioNTech on Cancer Drug - New Jersey Business & Ind...
BMS Announces $11.1 Billion Deal to Work with BioNTech on Cancer Drug New Jersey Business & Industry Association
Doctorx Unscripted Bold Conversations about Patient-Driven Science - Bristol Myers Squibb (BMS)
Doctorx Unscripted Bold Conversations about Patient-Driven Science Bristol Myers Squibb (BMS)
BMS taps biotech analyst from Goldman Sachs to lead long-term strategy - Fierce Biotech
BMS taps biotech analyst from Goldman Sachs to lead long-term strategy Fierce Biotech
BioNTech and Bristol Myers Squibb Partner in $10 Billion Oncology Agreement Focused on Immunother...
BioNTech and Bristol Myers Squibb Partner in $10 Billion Oncology Agreement Focused on Immunotherapy geneonline.com
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific - BioSpace
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific BioSpace
BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal - Fierce Biotech
BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal Fierce Biotech
Our technologies - Bristol Myers Squibb (BMS)
Our technologies Bristol Myers Squibb (BMS)
Encouraging the next generation to pursue STEM education - Bristol Myers Squibb (BMS)
Encouraging the next generation to pursue STEM education Bristol Myers Squibb (BMS)
Fierce Biotech Layoff Tracker 2025: Prothena lays off 63% of staff after ph. 3 trial fail - Fierc...
Fierce Biotech Layoff Tracker 2025: Prothena lays off 63% of staff after ph. 3 trial fail Fierce Biotech
Psoriasis around the world - Bristol Myers Squibb (BMS)
Psoriasis around the world Bristol Myers Squibb (BMS)
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer f...
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field Fierce Biotech
Post study drug access to BMS investigational medicinal products and approved products - Bristol ...
Post study drug access to BMS investigational medicinal products and approved products Bristol Myers Squibb (BMS)
Michael R. McMullen - Bristol Myers Squibb (BMS)
Michael R. McMullen Bristol Myers Squibb (BMS)
Our impact - Bristol Myers Squibb (BMS)
Our impact Bristol Myers Squibb (BMS)
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial - Clinical Tria...
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial Clinical Trials Arena
Our science - Bristol Myers Squibb (BMS)
Our science Bristol Myers Squibb (BMS)
Expanding access to lung cancer screening - Bristol Myers Squibb (BMS)
Expanding access to lung cancer screening Bristol Myers Squibb (BMS)
Science Firsthand: Predicting new possibilities in drug discovery - Bristol Myers Squibb (BMS)
Science Firsthand: Predicting new possibilities in drug discovery Bristol Myers Squibb (BMS)
BMS Pledges $40B Investment in US Despite Cost-Cutting Plans - BioSpace
BMS Pledges $40B Investment in US Despite Cost-Cutting Plans BioSpace
How BMS employees champion STEM education & diversity - Bristol Myers Squibb (BMS)
How BMS employees champion STEM education & diversity Bristol Myers Squibb (BMS)
Chris Boerner, PhD - Bristol Myers Squibb (BMS)
Chris Boerner, PhD Bristol Myers Squibb (BMS)
Building a better future: Bristol Myers Squibb 2023 ESG report - Bristol Myers Squibb (BMS)
Building a better future: Bristol Myers Squibb 2023 ESG report Bristol Myers Squibb (BMS)
Bristol Myers Squibb Announces Dividend - Yahoo Finance
Bristol Myers Squibb Announces Dividend Yahoo Finance
Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb (BMS)
Science Firsthand: Translating the promise of cell therapy Bristol Myers Squibb (BMS)
BMS to close Illinois site as part of cell therapy manufacturing consolidation - FirstWord Pharma
BMS to close Illinois site as part of cell therapy manufacturing consolidation FirstWord Pharma
Shaping a new era in cancer research - Bristol Myers Squibb (BMS)
Shaping a new era in cancer research Bristol Myers Squibb (BMS)
Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum - Fierce...
Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum Fierce Pharma
SportsCenter to be live at BMS before MLB Speedway Classic - Yahoo Sports
SportsCenter to be live at BMS before MLB Speedway Classic Yahoo Sports
Kuberaa Box Office Day 2 BMS Sales: Dhanush Takes Magical Jump Surpassing Every Single Telugu Fil...
Derica W. Rice - Bristol Myers Squibb (BMS)
Derica W. Rice Bristol Myers Squibb (BMS)
BMS growth driver Camzyos fails in heart disease trial, denting expansion opportunity - Fierce Ph...
BMS growth driver Camzyos fails in heart disease trial, denting expansion opportunity Fierce Pharma
Women innovators in AI transforming patient care - Bristol Myers Squibb (BMS)
Women innovators in AI transforming patient care Bristol Myers Squibb (BMS)
ESPN SportsCenter will be live at BMS prior to MLB Speedway Classic game on Aug. 2 - Speedway Digest
ESPN SportsCenter will be live at BMS prior to MLB Speedway Classic game on Aug. 2 Speedway Digest
BioNTech and Bristol Myers Squibb Partner on PD-L1xVEGF-A Antibody for Tumor Treatment - geneonli...
BioNTech and Bristol Myers Squibb Partner on PD-L1xVEGF-A Antibody for Tumor Treatment geneonline.com
BMS prevails in antitrust lawsuit over its defense of multiple myeloma blockbuster Pomalyst - Fie...
BMS prevails in antitrust lawsuit over its defense of multiple myeloma blockbuster Pomalyst Fierce Pharma
Advancing Lymphoma Treatment with Protein Degradation - Bristol Myers Squibb (BMS)
Advancing Lymphoma Treatment with Protein Degradation Bristol Myers Squibb (BMS)
FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer - Fierce Pharma
FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer Fierce Pharma
Predict First: BMS Executives Discuss Company’s AI Approach - Genetic Engineering and Biotechnolo...
Predict First: BMS Executives Discuss Company’s AI Approach Genetic Engineering and Biotechnology News
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug - Pharmaceutical Techn...
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug Pharmaceutical Technology
Chutes & Ladders—BMS oncology head swings to Syndax - Fierce Biotech
Chutes & Ladders—BMS oncology head swings to Syndax Fierce Biotech
Six BMS employees will participate in the 10th edition of the C2C4C cycle race - Bristol Myers Sq...
Six BMS employees will participate in the 10th edition of the C2C4C cycle race Bristol Myers Squibb (BMS)
Leveraging AI to enhance workplace innovation & efficiency - Bristol Myers Squibb (BMS)
Leveraging AI to enhance workplace innovation & efficiency Bristol Myers Squibb (BMS)
'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health reforms amid $40B US...
'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge Fierce Pharma
Over 500 BMS jobs axed in latest round of NJ cuts - FirstWord Pharma
Over 500 BMS jobs axed in latest round of NJ cuts FirstWord Pharma
Paula A. Price - Bristol Myers Squibb (BMS)
Paula A. Price Bristol Myers Squibb (BMS)
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb (BMS)
Pioneering Innovative Drug Development at Cambridge Crossing Facility Bristol Myers Squibb (BMS)
BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal - FirstWord Pharma
BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal FirstWord Pharma
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Inj...
BMS scales back at former Novartis plant, shifting cell therapy vector production to MA - Fierce ...
BMS scales back at former Novartis plant, shifting cell therapy vector production to MA Fierce Pharma
Deepak L. Bhatt, MD, MPH, MBA - Bristol Myers Squibb (BMS)
Deepak L. Bhatt, MD, MPH, MBA Bristol Myers Squibb (BMS)
BMS Commits $40B over Five Years to U.S. R&D, Manufacturing - Genetic Engineering and Biotechnolo...
BMS Commits $40B over Five Years to U.S. R&D, Manufacturing Genetic Engineering and Biotechnology News
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior An...
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model - Fierce Healthcare
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model Fierce Healthcare
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster p...
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan Fierce Pharma
Leading innovation in cardiovascular disease - Bristol Myers Squibb (BMS)
Leading innovation in cardiovascular disease Bristol Myers Squibb (BMS)
BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma
BMS's Camzyos falls short in Phase III non-obstructive HCM trial FirstWord Pharma
Cathi Ahearn - Bristol Myers Squibb (BMS)
Cathi Ahearn Bristol Myers Squibb (BMS)
Working at BMS - Bristol Myers Squibb (BMS)
Working at BMS Bristol Myers Squibb (BMS)
Karen H. Vousden, PhD - Bristol Myers Squibb (BMS)
Karen H. Vousden, PhD Bristol Myers Squibb (BMS)
BMS's Cobenfy disappoints as add-on therapy in schizophrenia study - FirstWord Pharma
BMS's Cobenfy disappoints as add-on therapy in schizophrenia study FirstWord Pharma
David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lun...
David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field Fierce Pharma
BMS Axes 516 More Employees in New Jersey - BioSpace
Advancing myeloma care: Taking action for the community - Bristol Myers Squibb (BMS)
Advancing myeloma care: Taking action for the community Bristol Myers Squibb (BMS)
Bristol Myers charts 500-plus new layoffs in New Jersey following expanded cost-savings drive - F...
Bristol Myers charts 500-plus new layoffs in New Jersey following expanded cost-savings drive Fierce Pharma
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia - BioSpace
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia BioSpace
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure - BioSpace
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure BioSpace
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success - BioSpace
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success BioSpace
BMS, Sanofi Settle Plavix Suit With Hawaii for $700M - BioSpace
BMS, Sanofi Settle Plavix Suit With Hawaii for $700M BioSpace
BMS expands SystImmune's ADC programme with first-line TNBC trial - FirstWord Pharma
BMS expands SystImmune's ADC programme with first-line TNBC trial FirstWord Pharma
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs - Fierce Pharma
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs Fierce Pharma
BMS's cost-cutting crusade continues to spill over into partnered programmes - FirstWord Pharma
BMS's cost-cutting crusade continues to spill over into partnered programmes FirstWord Pharma
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - Fierce ...
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma Fierce Pharma
BMS says subcutaneous version of Opdivo gets EU nod - FirstWord Pharma
BMS says subcutaneous version of Opdivo gets EU nod FirstWord Pharma
Advancing Cancer Treatment with KRAS Inhibitors - Bristol Myers Squibb (BMS)
Advancing Cancer Treatment with KRAS Inhibitors Bristol Myers Squibb (BMS)
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma - Fierce Pharma
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma Fierce Pharma
Bristol Myers Squibb CEO: Pharmaceutical innovation requires bold yet predictable U.S. policy - STAT
Bristol Myers Squibb CEO: Pharmaceutical innovation requires bold yet predictable U.S. policy STAT
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb Business Wire
Increasing fetal hemoglobin in sickle cell disease fact sheet - Bristol Myers Squibb (BMS)
Increasing fetal hemoglobin in sickle cell disease fact sheet Bristol Myers Squibb (BMS)
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials - Fierce ...
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials Fierce Biotech
BMS blames $1.4B impairment charge for Augtyro on 'evolving commercial' landscape - FirstWord Pharma
BMS blames $1.4B impairment charge for Augtyro on 'evolving commercial' landscape FirstWord Pharma
Friday Five — ASCO in review, Sanofi buys Blueprint, BMS buys into bispecifics…and more - FirstWo...
Friday Five — ASCO in review, Sanofi buys Blueprint, BMS buys into bispecifics…and more FirstWord Pharma
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III - BioSpace
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III BioSpace
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis - Fierce Pharma
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis Fierce Pharma
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts - BioSpace
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts BioSpace
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal - MedCity News
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal MedCity News
BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 tr...
BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 trial starts Fierce Pharma
Reaching more patients with cell therapy fact sheet - Bristol Myers Squibb (BMS)
Reaching more patients with cell therapy fact sheet Bristol Myers Squibb (BMS)
Former BMS Re employee sues over alleged noncompete enforcement - Insurance Business America
Former BMS Re employee sues over alleged noncompete enforcement Insurance Business America
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects - Fierce Biotech
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects Fierce Biotech
BMS bets $1.5B upfront on BioNTech's China-derived PD-L1/VEGF-A - FirstWord Pharma
BMS bets $1.5B upfront on BioNTech's China-derived PD-L1/VEGF-A FirstWord Pharma
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement - BioSpace
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement BioSpace
BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment - Clinical Trials ...
BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment Clinical Trials Arena
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™...